Galena Biopharma, Inc. GALE
No live quote for GALE yet.
Analyst view
Consensus: hold
Hold
Price target (mean) 8.00
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 2
- 2 months ago 2
- 3 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.15 | -0.15 – -0.15 | -0.49 | +69.4% | 0 | 0.0% | 1 |
| Next quarter | -0.14 | -0.14 – -0.14 | -0.45 | +68.9% | 0 | 0.0% | 1 |
| Current year | -0.59 | -0.59 – -0.59 | -2.36 | +75.0% | 0 | 0.0% | 1 |
| Next year | -0.84 | -0.84 – -0.84 | -0.59 | -42.4% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 5, 2017 | FBR Capital | Downgrade | — | Market Weight |
| Feb 1, 2017 | Maxim Group | Downgrade | — | Hold |
| Jun 28, 2016 | Raymond James | Downgrade | — | Market Perform |
| Mar 10, 2016 | Roth Capital | Maintained | — | Buy |
| Dec 7, 2015 | Cantor Fitzgerald | Upgrade | — | Hold |
| Nov 11, 2015 | Oppenheimer | Upgrade | — | Outperform |
| Sep 8, 2015 | Raymond James | Initiated | — | Outperform |
| Nov 19, 2014 | MLV & Co. | Maintained | — | Buy |
| Nov 3, 2014 | Cantor Fitzgerald | Maintained | — | Sell |
| Mar 19, 2014 | McNicoll Lewis Vlak | Maintained | — | Buy |
| Feb 17, 2014 | Cantor Fitzgerald | Downgrade | — | Sell |
| Nov 25, 2013 | Oppenheimer | Initiated | — | Outperform |
| May 21, 2013 | JMP Securities | Initiated | — | Market Outperform |
| Mar 24, 2013 | Needham | Initiated | — | Buy |
| Mar 18, 2013 | Maxim Group | Maintained | — | Buy |
| Dec 30, 2012 | PiperJaffray | Initiated | — | Overweight |
| Nov 27, 2012 | Aegis Capital | Initiated | — | Buy |
| Nov 26, 2012 | Dawson James | Initiated | — | Market Outperform |
| Oct 24, 2012 | McNicoll Lewis Vlak | Initiated | — | Buy |